• Kymera Therapeutics CFO Bruce N. Jacobs sold 77,109 shares on June 30, 2026 at weighted-average prices of $110.54 to $117.7.
• He also exercised stock options for 61,378 shares at $5.33.
• Jacobs ended the day with 244,883 shares beneficially owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-295090), on July 02, 2026, and is solely responsible for the information contained therein.